research Targeted expression of activated erbB-2 to the epidermis of transgenic mice elicits striking developmental abnormalities in the epidermis and hair follicles.
Activated erbB-2 in mice skin causes severe skin and hair abnormalities.
Search
for
Sort by
Research
870-900 / 1000+ resultsresearch Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.
research Novel small molecules downregulate CDK1 expression and inhibit Wnt/β-catenin signaling in cutaneous squamous cell carcinoma by targeting its distinct tumor-specific cellular landscape
Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.
research Loss of ERBB2 and ERBB3 Receptors Impacts Epidermal Differentiation in Mice
Losing both ERBB2 and ERBB3 receptors in mice causes significant skin problems and inflammation.
research A new target for squamous cell skin cancer?
Prostaglandins and the enzyme AKR1C3 could play a role in skin cancer and hair loss, and further research is needed to understand these mechanisms.
research Sorafenib stimulates human skin type mast cell degranulation and maturation
Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.
research Effects of anti-EGF serum on newborn mice
Anti-EGF serum affects growth and development in newborn mice.
research Advanced Inhibition of Undesired Human Hair Growth by PPARγ Modulation?
GMG-43AC may help reduce unwanted hair growth and treat certain hair loss conditions.
research Hair loss and Hedgehog inhibitors: a class effect?
Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
research Abiraterone and spironolactone in prostate cancer: a combination to avoid
Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
research Plerixafor Biases CXCR4 Signaling Through β-Arrestin to Promote Melanogenesis via β-Catenin–MITF Activation
Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Cepharanthine, a regulator of keap1-Nrf2, inhibits gastric cancer growth through oxidative stress and energy metabolism pathway
Cepharanthine can potentially treat gastric cancer by stopping tumor growth.
research Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib
Selumetinib causes fewer and less severe skin issues in children than binimetinib.
research Decision letter: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
The microenvironment affects the behavior and survival of melanocytes with the GNAQ oncogene in melanoma.
research Dual blockage of P-cadherin and c-Met synergistically inhibits the growth of head and neck cancer
Blocking both P-cadherin and c-Met can effectively stop head and neck cancer growth.
research Triple Hormonal Blockade (ADT3): A Patient’s Perspective
Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
research Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
research USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
research Therapeutic Androgen Receptor Ligands
Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
research 575 INTASYL self-delivering RNAi: A flexible platform to treat dermatological malignancies
INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
research Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
Setipiprant did not significantly improve hair growth in men with hair loss.
research Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled
Normal skin cell renewal doesn't need RAR signaling, but vitamin A-related skin thickening does.
research Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
research Evolving treatment paradigms in dermatology: Insights from emerging and repurposed therapies
New and repurposed treatments are improving outcomes in dermatology.
research Distribution and number of epidermal growth factor receptors in skin is related to epithelial cell growth
EGF receptors are crucial for skin cell growth and decrease with age.